Vanguard Trims Anika Therapeutics Stake to 8.7%

TL;DR

**Vanguard cut its stake in Anika Therapeutics to 8.7%.**

AI Summary

The Vanguard Group, a major investment firm, filed an amended SC 13G/A on February 13, 2024, disclosing its ownership in Anika Therapeutics Inc. As of December 29, 2023, Vanguard holds 1,023,803 shares of Anika's Common Stock, representing 8.7% of the company. This filing indicates a slight decrease in Vanguard's stake from its previous disclosure, which could signal a shift in their investment strategy for Anika Therapeutics.

Why It Matters

This matters because Vanguard is a significant institutional investor, and changes in its holdings can influence market perception and potentially the stock price of Anika Therapeutics.

Risk Assessment

Risk Level: low — This filing is a routine update from a large institutional investor and does not indicate any immediate, significant risk to the company or its shareholders.

Analyst Insight

An investor should monitor Anika Therapeutics' upcoming earnings reports and other institutional filings to understand the broader sentiment and any further shifts in major investor holdings.

Key Numbers

• 1,023,803 — Shares Owned (The total number of Anika Therapeutics Common Stock shares beneficially owned by The Vanguard Group as of December 29, 2023.)
• 8.7% — Ownership Percentage (The percentage of Anika Therapeutics' Common Stock owned by The Vanguard Group, indicating a significant but non-controlling stake.)

Key Players & Entities

• The Vanguard Group (company) — reporting person and institutional investor
• Anika Therapeutics Inc (company) — subject company whose securities are being reported
• 1,023,803 (dollar_amount) — number of shares of Common Stock beneficially owned by Vanguard
• 8.7% (dollar_amount) — percentage of Anika Therapeutics' class of securities owned by Vanguard
• December 29, 2023 (date) — date of the event which requires the filing of this statement

Forward-Looking Statements

• Anika Therapeutics' stock price may experience short-term volatility due to Vanguard's reduced stake. (Anika Therapeutics Inc.) — medium confidence, target: Q1 2024

FAQ

Filing Documents

• tv0293-anikatherapeuticsinc.htm (SC 13G/A) — 11KB
• 0001104659-24-020290.txt ( ) — 13KB

(a) - Name of Issuer

Item 1(a) - Name of Issuer: Anika Therapeutics Inc

(b) - Address of Issuer's Principal Executive Offices

Item 1(b) - Address of Issuer's Principal Executive Offices: 32 Wiggins Avenue Bedford, MA 01730

(a) - Name of Person Filing

Item 2(a) - Name of Person Filing: The Vanguard Group - 23-1945930

(b) – Address of Principal Business Office or, if none, residence

Item 2(b) – Address of Principal Business Office or, if none, residence: 100 Vanguard Blvd. Malvern, PA 19355

(c) – Citizenship

Item 2(c) – Citizenship: Pennsylvania

(d) - Title of Class of Securities

Item 2(d) - Title of Class of Securities: Common Stock

(e) - CUSIP Number

Item 2(e) - CUSIP Number 035255108

- Type of Filing

Item 3 - Type of Filing: This statement is being filed pursuant to Rule 13d-1. An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E).

- Ownership

Item 4 - Ownership: (a) Amount Beneficially Owned: (b) Percent of Class: (c) Number of shares as to which such person has: (i) sole power to vote or direct to vote: (ii) shared power to vote or direct to vote: (iii) sole power to dispose of or to direct the disposition of: (iv) shared power to dispose or to direct the disposition of: Comments: The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.

- Ownership of Five Percent or Less of a Class

Item 5 - Ownership of Five Percent or Less of a Class: If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following

- Ownership of More Than Five Percent on Behalf of Another Person

Item 6 - Ownership of More Than Five Percent on Behalf of Another Person: The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5%. Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company: Not applicable

- Identification and Classification of Members of Group

Item 8 - Identification and Classification of Members of Group: Not applicable

- Notice of Dissolution of Group

Item 9 - Notice of Dissolution of Group: Not applicable

- Certification

Item 10 - Certification: By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: February 13, 2024 By /s/ Ashley Grim Name: Ashley Grim Title: Head of Global Fund Administration

View Full Filing

View this SC 13G/A filing on SEC EDGAR